Application of Haemagglutination Inhibition Tests in the Follow Up of Choriocarcinoma: A Comparative Study by PERSIJN, J.-P. et al.
Persijn, Korstcn, Engelsman and Cleton: Haemagglutination Inhibition Tests in the Follow Up of Choriocarcinoma 403
Z. Klin. Chem. Klin. Biochern.
10. Jg. 1972, S. 403—409
Application of Haemagglutination Inhibition Tests
in the Follow Up of Choriocarcinoma: A Comparative Study
By J. P. PERSIJN, C. B. KORSTEN, E. ENGELSMAN and F. J. CLETON
From the Department of Clinical Chemistry (Head Dr.J. Persjjn) and the Department of Internal Diseases
(Head Dr. F.J. Cleton)9 Netherlands Cancer Institute, Amsterdam, The Netherlands
(Eingegangen am 4. Mai/26. Juni 1972)
The sequential course of urinary choriogonadotropin (HCG) levels was studied by commercial haemagglutination inhibition tests in three
patients suffering from chorionepithelioma. The data were correlated with bioassays and the clinical course of the disease. The test were
found to be clinically useful during treatment and follow up. No indications were found that the drugs used interfered with the HCG
assays.
Bei drei an Chorionepitheliom erkrankten Patientinnen wurde der zeitliche Verlauf der Choriongonadotropin (HCG)-Ausscheidung im
Harn mit käuflichen Hämagglutinations-Hemmtests verfolgt. Die Werte wurden mit den Ergebnissen biologischer HCG-Tests verglichen
und mit dem klinischen Verlauf der Erkrankung in Beziehung gesetzt. Die Tests erwiesen sich als klinisch brauchbar für die Kontrolle der
HCG-Ausscheidung unter der Behandlung. Für eine Störung der HCG-Bestimmungen durch die den Patientinnen verabreichten Medi-
kamente ergab sich kein Anhalt.
For the diagnosis and control of the treatment of
placental Choriocarcinoma a knowledge of the urinary
excretion of human chorionic gonadotropin (HCG) is
indispensable (1).
Several methods for assaying HCG from urine have been
described, including the techniques of bioassay, radio-
immunoassay, or the haemagglutination inhibition test.
Our bioassay is susceptible to subjective interpretation
and it suffers from the other disadvantage of inadequate
sensitivity to low levels of HCG. The radio-immuno-
assay has the attractive advantage of giving an absolute
value for HCG. It demands, however, a big outlay in
money and equipment, and like the bioassay it takes
several days to obtain results (2, 3). Test kits for the
haemagglutination inhibition test of HCG, containing
sheep erythrocytes coated with HCG and the antiserum
to HCG are commercially available.
We have used two commercial tests (Pregnosticon and
Luteonosticon) which provide results within 2 and 8
hours respectively. The tests are simple to perform. The
former is designed as a pregnancy test and is a direct test
for HCG. The Luteonosticon test has been developed
primarily for the assay of LH by making use of the cross
reactivity between antiserum against HCG and LH.
This implies that in the very low ranges, LH rather than
HCG is expected to be measured. Whereas the Pregnosti-
con test requires urine containing more than 1500 IU/1
for a positive result, the Luteonosticon test is capable of
detecting 10 III HCG (or 25 IU LH) per liter urine.
This means that nearly the whole range of HCG ex-
cretion levels to be expected in patients suffering from
Choriocarcinoma can be covered by using both tests.
Only in cases of very low HCG titers does the lack of
discrimination between LH and HCG prevent a correct
interpretation of the assay result in terms of HCG. The
present paper describes the sequential course of HCG
excretions from patients suffering from Choriocarcinoma.
Both tests, Pregnosticon and Luteonosticon, were used
throughout the follow up, depending on the amount of
HCG excreted. The results are related to the clinical
data of the patients. For comparative purposes, several
urine samples were tested for HCG by bioassay.
Methods and Materials
Haemagglutination inhibition test
The HCG assays were performed with the haemagglutination in-
hibition tests Pregnosticon All-in and Luteonosticon (Organon,
Oss, the Netherlands).
Principle of the test
Erythrocytes coated with HCG retain their capacity to settle in a
ring formation, provided tubes with a hemispherical bottom are
used.
The presence of antibodies to HCG will inhibit this ring formation.
If a sample contains HCG sufficient to block the action of the anti-
bodies the formation of a ring pattern will therefore be uninhibited
(4, 5, 6).
Pregnosticon All-in is standardized on a level of 1500 IU HCG/1
urine, using the 2nd International Standard for HCG as a standard
preparation.
Luteonosticon is prepared using carefully chosen antisera which
possess such cross reactivity to LH that 2.5 IU LH show a haemag-
glutination inhibition activity comparable to that of 1 IU of HCG.
As Luteonosticon is standardized on a level of 25 IU LH/1 urine
(2nd IRP — HMG) this can be 'translated' into 10 IU of HCG.
Procedures for the Pregnosticon and Luteonosticon
tests
Twenty four hour urine samples were collected, in which assays
for creatinine were performed to control complete collection.
Urine samples were kept frozen unless assayed immediately.
Freezing and thawing, even when done twice, did not affect the
results. After thawing completely the sample was well mixed
and centrifugcd. Dilutions were made up with 0.1% bovine scrum
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albumin solution in physiological saline to prevent adsorption of
HCG or LH to the glass wall.
There are two points which, if not considered properly, may lead
to erroneous results. All reagents used must belong to the same
batch. Secondly, any vibration during the formation of the sedi-
mentation patterns should be avoided.
Dilution scheme
Serial dilution of a sample allows one to estimate, from the sedi-
mentation pattern, the upper and lower limits of the range in which
true HCG concentration exists. The highest dilution still giving
an agglutination inhibition (ring formation) is taken for the calcula-
tion of the lower limit of the range. For the calculation of the upper
limit the lowest dilution is used, still giving an intermediate
pattern, or a diffuse sedimentation. Thus the number of dilutions,
and the extent to which they are performed, determine the limits
of these ranges. In selecting a scheme for dilutions one must
compromise. The desire to express the results in narrow ranges
conflicts with the demands of practice and economy. As a compro-
mise, a schedule for the dilution series has been set up which
allows the results to be expressed in narrow ranges for low levels,
but in more expanded ranges as levels tend to become higher.
As soon as HCG excretions fall into the range of normal values
for LH, therapeutic treatment has to be continued for some
period to eliminate remaining small aggregations of tumour cells
(1). During this period the levels of HCG excretions have to be
estimated within narrow ranges to detect any recurrence of the
disease. Therefore, the above mentioned schedule meets the diag-
nostic requirements. Since the schedule used in this study deviates
from the one given by the manufacturers of the tests the full
dilution scheme will be presented below:
Samples containing 7,000—30,000 IU/ί HCG
Assays were performed according to the procedure described in the
leaflet delivered with each Pregnosticon test, but with a modifica-
tion: To the opened ampoules, numbered 1, 2 and 3, 0.1 ml urine
diluted 1:5, 1:10 and 1:20 respectively was added. Thereafter the
instruction leaflet was followed. Test results can be read after
a period of two hours. A complete agglutination inhibition is
revealed by a clear ring formation. The minimum amount of HCG
necessary for ring formation is 0.15 IU. Considering the highest
dilution (a) which still gives a ring, the minimum amount of HCG
to be expected in the urine can be calculated by
0.15 X 10,000 X dilution factor a (eq. 1)
The result of equation (1) represents the lower limit of the HCG
range. The next ampoule in the dilution series (b) will show either
no ring or a diffused transitional pattern.
The urine will therefore contain at most an amount of HCG equal
to
0.15 X 10,000 X dilution factor b (eq. 2)
The result of equation (2) represents the upper limit. Table 1
summarizes the possible results (IU/1).
Samples containing more than 30,000 IU// HCG
To the opened ampoules, numbered 1, 2, 3 and 4 of the Pregnosti-
con test, O.lml urine diluted 1:50; 1:100; 1:500 and 1:1,000
Tab. 1
HCG concentration ranges as read from the sedimentation pattern and
calculated from equations (1) and (2). The sign -f denotes ring forma-
tion, the sign —, indistinct or no ring formation (Pregnosticon 'test)
Tab. 2
HCG concentration ranges as read from the sedimentation pattern and
calculated from equations (1) and (2). The sign -f denotes ring forma-
tion, the sign —, indistinct or no ring formation (Pregnosticon test)
Ampoule
number
Dilution
1
1:50
-f
-f
4-
-f-
2
1:100
-f '
_|_
—
3
1:500
4-
+
—
4 HCG concentration
range
1:1000 IU/1
+ < 1,500000
— 750,000—1,500000
1
 — 150,000— 750,000
— 75,000— 150,000
— 30,000— 75,000
respectively was added. Otherwise the assays were performed
following the instruction leaflet. Table 2 summarizes the possible
results as calculated from equations (1) and (2).
Samples containing less than 7,000 IU/I HCG
As a rule samples from new patients were checked with the method
described for samples containing 7,000^30,000 IU/1 HCG. If
ring formation was absent in all of the ampoules, the urine was
assayed with the Luteonosticon test. The sensitivity of this test is
mainly due to the following steps : Incubation with -the antiserum
(2 — 4h), and a second incubation period of 30—60 min after
adding the sensitized erythrocytes. After centrifuging and washing,
the erythrocytes are resuspended in a small volume allowing the
sedimentation pattern to be read within two hours. For more
details, the reader is referred to ref. 1. c. (4), (5) and (6).
The protocol of the Luteonosticon test was followed with modi-
fications :
1. All samples were put in a waterbath at 95QC for 5—10 rriin. After
cooling and centrifuging the urines were diluted 1:20.
To the tubes numbered 1 — 5 containing the antiserum were added
0.0; 2.0; 4.0; 5.0 and 5.5 ml of diluent. The latter was prepared as
prescribed in the instruction leaflet. The contents were made up to
6.5 ml with the diluted sample.
2. If the urine was expected to contain less than 200 IU/1 HCG the
sample was diluted only 1:5. To the tubes numbered 1, 2 and 3
containing the antiserum (0.5ml) 0.0; 2.0 and 4.0ml of diluent
were added. The contents were made up to 6.5 ml with the diluted
sample.
The test is then adjusted to give a ring formation, if the mixture
contains at least 0.06 IU HCG. If therefore, in a series, two suc-
cessive tubes containing respectively "c" and "d" ml diluted urine
are characterized by a positive and a negative result the HCG
content can be expressed by the range
0.06 X - — 0,06 X X dilution factor (eq. 3)
Ampoule number
Dilution
1 2 3
HCG concentration
range
1:5 1:10 1:20 IU/1
-h -f > 30,000
-f- — · 15,000-^30,000
— — 7,500—15,000
— — < 7,500
Table 3 summarizes possible results as derived from equation (3).
The results "higher than 2,400 IU/1" with the Luteonosticon test
and "less than 7,000 IU/1" with the Pregnosticon test for a given
sample are interpreted solely as 2,400—7,000 IU/1.
Normal range (expressed in terms of HCG)
The acceptable normal range is derived from the LH levels found
in normal premenopausal subjects. *
These are less than 50 IU/24 h, except for the ovulatory phase in
which LH levels expressed as HCG units can rise to 240 IU/24 h.
Bioassay
The bioassay was performed by a modification of the ASCHHEIM
and ZONDEK method as described by BOOT et al. (7). Briefly,
3 — 4 week old female mice were given three subcutaneous injec-
tions of 0.05 ml urine on day 1 and 2. For this, early morning urine
samples, diluted (1:10; 1:100 or 1:1,000) or undiluted were used.
Vaginal smears were taken ofi days 4 and 5. At autopsy on day 5,
the presence or absence of corpora lutea was noted, as well as
follicle development and uterine or ovarian size.
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Tab. 3
HCG concentration ranges as read from the sedimentation pattern and
calculated from equation (3). The sign -h denotes ring formation, the
sign —t indistinct or no ring formation (Luteonosticon test)
Tube number
ml diluted
urine
1
6.0
2
4.0
3
2.0
4
1.0
5
0.5
HCG con-
centration
range
IU/1
Dilution 1:20 — — —
ml diluted
urine 6.0
Dilution 1:5 —
4.0 2.0
— —. < 200
— — 200— 320
_ — 320— 600
— _ 600—1,200
+ — 1,200—2,400
-I- + > 2,400
< 50
50— 75
75— 150
> 150
The limits of detectability are: less than 100 IU/1; 100—1,000;
1,000—10,000 and ΙΟ4—105 IU/1.
Construction of graphs
Upper and lower limits of the concentration ranges as obtained by
haemagglutination inhibition tests were multiplied by the 24 h
urine volume (litres). The limits obtained by the bioassay are
expressed as IU/litre. All values are plotted on a logarithmic scale.
The lower limits of detectability are 50 IU/1 and 100 IU/1 for the
Luteonosticon test (using the dilution scheme presented here) and
the bioassay respectively.
Negative results with these tests will therefore be expressed in the
figures by a single dash or drcle on the level of 50 and 100 IU/24 h
regardless of the 24 hour volume.
Clinical Studies
Two patients are shown in which the treatment was not effective.
This was, presumably, because of the long delay before the diagnosis
was made. In one patient the diagnosis was made early and the
result of the treatment was as favourable as might be expected.
Case No. 1
This concerns a woman of 26 years. Since May 1971 she experienced
irregular vaginal blood loss; in September on gynaecological
examination a tumour was seen near the ostium cxternum of the
uterine cervix.
The tumour was resected. Histology: choriocarcinoma. There were
no signs of lung metastases. The patient was then referred to our
clinic. Pelvic arteriography showed no pathology. Treatment was
started immediately. The further course of the disease during
treatment is illustrated in figure 1. After HCG excretions had
reached consistently normal range three additional courses of
chemotherapy were given.
Case No. 2
refers to a woman of 29 years. After the birth of her second child
(June 1970) she experienced irregular blood loss. Diagnosis of
choriocarcinoma was made in July 1971 on a biopsy of vaginal
metastases. The patient was then referred to our clinic. Multiple
lung metastases were found. Standard treatment with methotrexate
and actinomycin D had no effect.
The further course of the disease during treatment is illustrated in
figure 2. The patient died of progressive lung metastases in De-
cember 1971.
Case No. 3
concerns a woman who had her only child in 1967. She had
abortions in 1968 and 1970. In June 1971 after six months of
irregular blood loss, a vaginal tumour was found. A biopsy from
this tumour was diagnosed as being "suspect". Two months later
a second biopsy was taken; histological diagnosis: choriocarcinoma.
In September 1971, the patient was referred to our clinic.
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Fig. 1
Case no J. Variation of HCG excretions with time, as measured by haemagglutination inhibition test ([1U/24 l i ] ·—·) and by bioassay ( f l U / I j
ο—ο). The upper and lower dash represent upper and lower limits of detectability. The sign Μ denotes time of menstruation. Chemotherapv
is indicated on the head of the graph. Time zero is 16 Sept. 1971. The prints with arrows indicate the detection limit
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Case no 2. Variation of HCG excretions with time, as measured by haemagglutination inhibition test ([IU/24h] · — ·) and by bioassay([IU/1] o— o). The upper and lower dash represent upper and lower limits of detectability, chemotherapy is indicated on the head of the
graph. Time zero is 26 Sept. 1971
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Fig. 3
miiiiJ0 3' xVail?tion of HCO excretions with time, as measured by haemagglutination inhibition test ([iU/24 h] ·-—) and bioassay([IU/1] o—o). The upper and lower dash represent upper and lower limits of detectability. Chemotherapy is indicated on the head of the
graph. The sign O denotes time of operation, the sign Μ start of the menstruation. Time zero is 10. Sept 1971
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Tab. 4
Recovery experiments using urine samples from patients subjected to different kinds of therapy
P => Pregnosticon test; L = Luteonosticon test
Expert» Sample
ment No.
1 A
B
1 vol A + 2 vol B
2 A
B
1 vol A -f 5 vol B
3 A
B
1 vol A + 3 vol B
4 A
B
1 vol A + 4 vol B
5 A
B
1 vol A -}- 2 vol B
6 A
B
I vol A + 6 vol B
7 A
B
1 vol A + 11 vol B
8 A
B
1 vol A -f 5 vol B
9 A
B
1 vol A -f 15 vol B
10 A
B
1 vol A -f 6 voi B
Therapy
none
none
none
actinomycin-D and
methotrexate
mothotrexate
actinomycin-D
none
none
N-mustard
and vinblastin
actinomycin-D
bleiomycin and
actinomycin-D
actinomycin-D
N-mustard and
vinblastin
methotrexate
bleiomycin and
actinomycin-D
methotrexate
methotrexate, acti-
nomycin-D and bleio-
mycin
none
actinomycin-D and
bleiomycin
none
Found
(IU/1)
30,000— 75,000
<50
7,500— 15,000
600— 1,200
<50
75— 150
200— 320
<50
75— 150
30,000— 75,000
600— 1,200
7,000— 15,000
75,000—150,000
15,000— 30,000
30,000— 75,000
7,500— 15,000
200— 320
1,200— 2,400
75,000—150,000
1,200— 2,400
7,500— 15,000
7,500— 15,000
75— 150
1,200— 2,400
1,200— 2,400
<50
75— 150
7,500— 15,000
<50
1,200— 2,400
Calculated
(IU/1)
_
—10,000—25,000
—
100— 200
—
—50— 110
—
—6,000—16,000
—
—35,000—70,000
—
—1,240— 2,400
—
—7,300—14,500
—
—1,300— 2,600
—
—75— 150
—
—1,250— 2,500
Test
P
L
P
L
L
L
L
L
L
P
L
P
P
P
P
P
L
L
P
L
P
P
L
L
L
L
L
P
L
L
X-ray showed multiple lung metastases and on arteriography,
indications of pelvic metastases were found. Chemotherapy was
started with two courses of methotrexate. The further course of
the disease during treatment is illustrated in figure 3.
Results
Recovery experiments were performed to determine
whether acceptable continuity existed between both
tests: Pregnosticon and Luteonosticon. Table 4 con-
tains results from these experiments, in which both
original urine samples and mixtures of these were
assayed for HCG content. For the analyses, tests with
different batch numbers were used. The agreement
between calculated and observed ranges is satisfactory.
Figures 1—3 show the urinary excretions of HCG as
determined with the tests arid bioässays. In figure 1,
there is a good agreement between the results of both
assays, especially at the beginning and at the end of the
treatment. For unknown reasons, the bioassay shows
slightly elevated levels of HCG during a period (2nd
and 3rd months in fig. 1) in which the haemagglutination
inhibition tests give periodically negative results. For the
bioassay early morning urine samples were used. It
seems reasonable to assume that the early morning urine,
by its higher concentration of HCG as compared to the
24 hours sample, constitutes a borderline case, which is
measured as elevated. The periods with continuously
negative results with both types of assay, co-incide com-
pletely. These tests remained negative for some more
weeks (not indicated in the figure). Figure 2 illustrates
only part of the clinical course of case No. 2. Initial
standard treatments with methotrexate and actinomycin-D
had no effect.
Vaginal metastases had regressed significantly at the
time indicated by the left arrow. Chest X rays,
however, showed that pulmonary metastases did not
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regress, but in fact started to increase about three
months after the onset of therapy. Clinical signs of
pulmonary insufficiency were observed from the time
indicated by the right arrow. The patient died one week
later (December 1971). The figure shows (left) the
temporary effect of the therapy and (right) the increase of
HCG levels which corresponded with progressive
disease.
Figure 3 (case No. 3) shows good agreement between
both assays. There was some regression of the lung
metastases and the gonadotropin excretions went down.
Hysterectomy and ovariectomy was performed at the
time, as indicated by the arrow, because of the progres-
sive nature of the disease. Pelvic arteriography had
shown the existence of tumour masses in the uterus
and the parametria.
Lung metastases and HCG excretions remained station-
ary for about three weeks only to become progressive
thereafter.
Discussion
The cells of trophoblastic choriocarcinoma retain their
ability to produce gonadotropins. The levels of HCG
excretions are more or less representative of the number
of tumour cells. The prognosis of choriocarcinoma can
be very favourable if the disease is diagnosed early and
treated adequately. The latter means that when the
tumour responds to chemotherapy and, consequently,
HCG excretions have reached normal levels, still two or
more courses of chemotherapy must be given to destroy
residual tumour tissue. BAGSHAWE (1) has pointed out
that in a patient whose HCG excretion has become nor-
mal there could be up to 10s tumour cells present.
Therefore, continuation of therapy cto kill the last
tumour cell' (BAGSHAWE) is a pre-requisite to prevent a
relapse.
From the above, it is of the utmost importance to
estimate correctly the^ beginning of the phase of con-
sistently negative HCG excretions (i. e. equal to the
expected LH levels). From figure 1, it is evident that for
this purpose a multitude of frequently performed con-
secutive HCG determinations are necessary. In this
figure the normal range is outlined as less than 50IU.
There are two well-known instances where, as a conse-
quence of LH production, values higher than 50 IU/24 h
must be taken as the limit of the normal range. During
the ovulatory phase there is a short period of elevated
LH production, which may result in excretion levels up
to 240 IU/24 h (HCG units), and which, obviously,
has to be considered in the interpretation of the results.
Secondly, ovariectomy disturbs the feed back mecha-
nism of ovarian hormones on the excretion of LH.
According to ERB and RICHTER (8) and DEMOL et al. (9)
the increase of urinary LH after ovariectomy may vary
from 50 IU/24 h to about 500 IU/24 h. This individual
variation makes it necessary to establish the normal
range for ovariectomized patients separately.
Tab. 5
Comparison of results (IU/1) of HCG analyses by haemagglutination
inhibition test with bioassay and radioimmunoassay
Sample
1
2
3
4
5
6
7
Haemagglutination
inhibition test
<50
<50
<50
75—150
75—150
<50
75—150
Bioassay Radioimmunoassay
<100 31
— 42
<100 83
ipp — 1,000 120
100—1,000 81
<100 30
100—1,000 40
The temporary rise in HCG excretion, which is some-
times seen during and after the first successful courses of
therapy, and which may be ascribed to the liberation of
HCG from cells killed by chemotherapy, need not lead
to interpretation problems.
A question which has not received much attention in the
literature is whether drugs (or their metabolites) present
in the urine may influence the assay of HCG. It seems
that the results of recovery experiments (table 4) strong-
ly argue against any influence. Additional support can
be found in the course of the results of the haemaggluti-
nation inhibition tests, as compared with those from
bipassays: the latter being based on entirely different
principles. In a few cases there is a discrepancy, in the
sense of a brief opposite effect to the findings of the bio-
assay and the haemagglutination inhibition tests (see
fig. 1 and 3). There is no indication that such a discre-
pancy is related to the drug applied.
We feel that the haemagglutination inhibition tests can
be used for management of chorio-carcinoma. Since,
however, in this disease so much depends on the
reliability of HCG determinations, we would like to
comment on the control of the assay. Regular checks of
the HCG analyses with another type of assay (preferably
a radio-immunoassay), seems mandatory, especially in
the lower ranges. Table 5 gives some examples of checks
of results of HCG analyses obtained by haemaggluti-
nation inhibition tests, with a bioassay and a radio-
immunoassay.
No standard is delivered with the commercial tests used
in this study. As an additional control we recommend
the preparation of a combined urine sample, containing
200-300 IU HCG/1, which should be divided into
equal amounts and stored deep frozen. One portion
should be run together with the routine. sample as an
additional control.
By choice: the bioassay which calls for a great deal of
experience does not seem preferable. The introduction
of radio-immunoassays in the clinical laboratory be-
comes attractive if a regular supply of a krge number of
specimens is expected for a period of years. Even under
these circumstances it will be of importance to have
haemagglutination inhibition tests at hand which are
.simple in performance. Radio-immunoassays are known
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the clinic one can easily rely on haemagglutination P* BOONMAN and Miss A. W. M. BON for their most competent
. , . , . .
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